Trump considers reviving a proposal that cuts US drug prices to international levels: It could be another blow to the drug industry, on top of ongoing drug price cuts in Medicare and looming tariffs set to hit the sector.
Only 30% of healthcare and pharma AI pilots make it to production: AI companies must demonstrate tech prowess, address security concerns, and drive clinical or business outcomes to convert more pilots into full-scale implementation..
RFK Jr.’s MAHA vision receives support in Indiana: Gov. Mike Braun issued nine executive orders aligning with Kennedy’s chronic illness agenda. But cuts to Medicaid funding could prevent these initiatives from having their intended effect.
The walls are closing in on the largest pharmacy benefit managers: Vertically integrated healthcare conglomerates may soon have to separate their pharmacy operations from their PBM businesses.
Lilly notches another win in oral GLP-1 drugs: Eli Lilly’s phase 3 success could put it in a commanding position in diabetes and weight loss if the easy-to-take—and cheaper to manufacture—drug is approved.
Trump says his drug pricing executive order will lower medication costs for Americans: But that could depend on how the Inflation Reduction Act’s “pill penalty” is addressed. The pharma industry is watching closely.
Abbott estimates millions in tariff costs, but may blunt some effects with $500 million investment in new US manufacturing: Pharma manufacturers currently under reprieve should pay attention to medtech industry effects and strategy shifts.
Health insurers’ digital tools lack basic capabilities: Medicare Advantage insurers must improve the digital experience since members can switch plans each year.
Pfizer’s push into weight-loss drugs suffers another setback: Novo Nordisk and Eli Lilly are cornering the market as pharma companies struggle to develop an effective weight-loss drug pill.
Rapidly growing healthcare providers are reinvesting in online marketing: Incumbents must embrace social and search marketing to ward off competition from telehealth and D2C providers.
Brand-name drug prices could see the biggest jumps under newly promised tariffs: The Trump administration’s renewed push for pharma tariffs would mean higher drug manufacturing costs across the board, but especially for brand-name medicines.
Online health information drives consumer decision-making: It’s an opportunity for healthcare and pharma brands and marketers to turn consumers into customers—and patients.
Physicians aren’t burning out at the same rate as the COVID years: While doctor burnout rates are improving, it’s likely not enough progress to significantly impact turnover rates, and expense, to the healthcare system.
Novartis is the latest Big Pharma company to invest billions in US production capacity: The largest drugmakers continue moving manufacturing to the US as the industry awaits Trump’s tariff plan for pharma. Generic drugmakers—which supply 90% of US prescriptions—won’t have the same maneuverability.
The number of ‘cost desperate’ patients reaches a new high: Healthcare affordability challenges are worsening for many of the folks who need the most support. We explore how healthcare providers and marketers can step up.
Digital health investing grew to $3 billion in Q1: However, the market stability investors count on to make long-term investments is in short supply amid sweeping federal spending and agency changes.
New CMS head suggests AI avatars could replace clinicians: He’s not alone, but we’re dubious—and of the mindset that human relationships are still the bedrock of a high-quality patient experience.
Patients want more digital health support from drug companies: Respondents in a recent survey say it would improve their worsening perception of pharma.
HHS’ massive FDA layoffs could delay food and drug inspections, approvals: HHS denies cuts will affect food and drug safety inspections and drug approvals, but a swath of FDA experts are concerned about drug innovation, review processes, and manufacturing safety.